aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting

On November 19, 2026 aTyr Pharma, Inc. (Nasdaq: ATYR) ("aTyr" or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, reported a poster presentation featuring preclinical data for ATYR2810, a monoclonal antibody targeting neuropilin-2 (NRP2), at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, which is being held November 18 – 21, 2026, in Seoul, South Korea.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Osteosarcoma remains a significant unmet medical need with standard therapy that has not meaningfully improved survival in decades and patients facing very poor outcomes, particularly once the disease spreads to the lungs. The differentiated approach of ATYR2810 in targeting NRP2 positions it as a highly promising therapeutic candidate, as the potential to reduce metastases and sustain anti-tumor effects after treatment ends, without evidence of overt toxicity, could meaningfully improve outcomes for patients and families facing this devastating disease," said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

"ATYR2810 has shown anti-tumor effects in multiple preclinical models of aggressive cancers where NRP2 is implicated, and NRP2 has been shown to play a role in osteosarcoma angiogenesis and metastasis, which is in large part driven by an immunosuppressive tumor microenvironment," said Leslie A. Nangle, Ph.D., Vice President, Research at aTyr. "This latest research further supports that ATYR2810 can reprogram tumor-associated macrophages and that by targeting NRP2, ATYR2810 monotherapy can lead to substantial inhibition of tumor growth in osteosarcoma preclinical models, including human patient-derived orthotopic models and an aggressive syngeneic mouse model, as well as outstanding effects on tumor recurrence after removal of drug at day 25, with effects lasting out to 45 days. Furthermore, a reduction in lung metastases, a devastating complication of osteosarcoma, was also observed. We believe these findings provide a strong rationale for translating NRP2 inhibition into clinical studies."

Details of the poster presentation appear below. The poster is available on the aTyr website.

Title: Neuropilin-2 as a Therapeutic Target in Osteosarcoma: Spatial Transcriptomics and In Vivo Testing of a Clinic-Ready Anti-Neuropilin-2 Antibody
Session: Basic Science: Translational & Preclinical Research
Poster Number: 74
Date and Time: Thursday, November 19, 2026 from 5:30PM – 6:30PM KST
Location: Hall D, 3F, Coex Convention Center, Seoul, South Korea

The poster presents preclinical research evaluating the use of ATYR2810 in clinically relevant models of osteosarcoma, including primary tumors and lung metastases, utilizing spatial transcriptomics and in vivo testing. Treatment with ATYR2810 in mice was associated with reduced tumor growth and metastasis without evidence of overt toxicity. Furthermore, NRP2 was expressed on malignant osteosarcoma cells and macrophages, suggesting a potential mechanism driving disease progression.

Pediatric osteosarcoma is the most common type of primary malignant bone cancer in children and adolescents, with approximately 1,000 new cases diagnosed every year in the U.S. While osteosarcoma is a bone cancer, it can spread to other organs and tissues in the body, most commonly starting with the lungs. The current standard of care typically includes a combination of chemotherapy and surgery, including limb-sparing surgery. Limb amputation is required in approximately 10% of cases. About 40% of those treated for osteosarcoma will experience a relapse or recurrence. Research that explores the underlying causes and mechanism of metastatic disease may lead to new treatments that can address and manage recurrence, which are greatly needed.

About ATYR2810

ATYR2810 is a fully humanized monoclonal antibody that is designed to specifically and functionally block the neuropilin-2 (NRP2) receptor. NRP2 is a cell surface receptor that is highly expressed in many tumors and is strongly implicated in more aggressive cancer progression, drug resistance development and metastatic spread. Recent data has demonstrated that the expression of NRP2 is also associated with the development of an immunosuppressive tumor microenvironment in a variety of tumors that do not respond to classical checkpoint inhibitors. Increased NRP2 expression is associated with worse outcomes in many cancers, including osteosarcoma, triple negative breast cancer, prostate cancer and pancreatic cancer. ATYR2810 is in preclinical development for the treatment of aggressive cancers where NRP2 is implicated, having successfully completed GLP toxicology testing in non-human primates and cGMP manufacturing.

(Press release, aTyr Pharma, NOV 19, 2026, View Source [SID1234675001])

Ethics Approval for Amplia’s Accent-Mini Trial

On November 19, 2026 Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF) ("Amplia" or the "Company") reported that it has received ethics approval for its ACCENT-Mini trial in metastatic pancreatic cancer. Ethics approval is a key milestone in launching a clinical study, allowing patient recruitment to begin as soon as site approvals are finalised.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ACCENT-Mini will evaluate daily dosed narmafotinib in combination with the chemotherapies gemcitabine and Abraxane. The trial builds on the encouraging results of the ACCENT trial, in which intermittently dosed narmafotinib plus chemotherapy improved outcomes across all measures of activity compared to chemotherapy alone. Notably, ACCENT delivered a complete response rate of 7.8% and a median overall survival of 11.1 months, with no significant changes to the tolerability profile of chemotherapy alone.

Three (3) clinical trial sites in Australia have been selected for ACCENT-Mini, and trial start-up activities at all sites are well advanced.

Safety and pharmacokinetic data from ACCENT-Mini are expected in late Q1/early Q2 2027. These data will form part of Amplia’s protocol submission to the FDA for the registrational study of narmafotinib in pancreatic cancer.

The ACCENT-Mini trial is an important step in Amplia’s strategy to build the clinical evidence for narmafotinib as a partner drug in combination treatments for hard-to-treat cancers, including pancreatic cancer. A major challenge in these cancers is that tumours often become resistant to both existing treatments and newer targeted medicines, such as KRAS inhibitors, limiting how effectively they work. Amplia believes narmafotinib has the potential to help overcome this challenge and make these treatments more effective for patients.

Amplia Therapeutics CEO and MD Dr Chris Burns commented: "We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options. Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini."

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

(Press release, Amplia Therapeutics, NOV 19, 2026, View Source [SID1234675025])

INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis

On November 18, 2026 INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, reported that it has submitted a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) for VOCERYQ (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously referred to as INO-3107, as a treatment for adults with RRP.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Building on the recent FDA approval of VOCERYQ, we believe there’s significant opportunity to transform the treatment paradigm for RRP in Europe, a region that currently has no approved non-surgical treatment options that target the root cause of RRP," said Dr. Michael Sumner, Chief Medical Officer of INOVIO. "We look forward to working closely with the EMA during the review and hope to ultimately provide RRP patients with a much-needed new treatment option that reduces the need for surgery."

"Clinicians and patients alike understand that every surgery matters, because every surgery puts a patient’s vocal cords at risk," said Frederik Dikkers, Professor emeritus of Otorhinolaryngology / Head and Neck Surgery at Amsterdam University Medical Center (Amsterdam UMC). "RRP affects patients around the world, and this submission is a meaningful step forward for those in Europe who have waited far too long for relief from this debilitating disease."

The CMA application is supported by a comprehensive set of preclinical, clinical, and manufacturing data, including results from INOVIO’s clinical studies for VOCERYQ published in in 2025 in Nature Communications and The Laryngoscope. An additional analysis of the data was published in October 2026 in The Laryngoscope under the title DNA Immunotherapy (INO-3107) Long-Term Efficacy Supported by Enhanced Immunogenicity in HPV-6/11 RRP.

The European Commission granted Orphan Drug designation to INO-3107, now VOCERYQ, for the treatment of RRP in 2023. INO-3107 also received an Advanced Therapy Medicinal Product (ATMP) Certification from the EMA’s Committee for Advanced Therapies (CAT) after review of chemistry, manufacturing and controls (CMC) and nonclinical data. This certification confirms that the data reviewed complies with the standards that would be used to evaluate a European marketing authorization application. INOVIO submitted the marketing authorization application using guidance from pre-submission meetings with EMA and the Rapporteurs. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.

The U.S. Food and Drug Administration (FDA) granted VOCERYQ accelerated approval on October 30, 2026 for adults with RRP to reduce the frequency of surgery. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory study(ies). INOVIO expects to make VOCERYQ available to order and ship in the U.S. in approximately 60 days from the date of FDA approval, with full commercial launch expected in the first quarter of 2027.

About Recurrent Respiratory Papillomatosis
Recurrent Respiratory Papillomatosis (RRP) is a rare, debilitating disease caused primarily by HPV-6 and/or HPV-11. RRP is characterized by the development of small, wart-like growths, or papillomas, in the respiratory tract. While papillomas are generally benign, they can cause severe, life-threatening airway obstruction and respiratory complications. RRP can also significantly affect quality of life for patients by affecting the voice box, limiting the ability to speak effectively. Surgery to remove papillomas is the current standard of care for RRP; however, the papillomas often grow back. INOVIO’s market research to date with patients and healthcare professionals indicates that a reduction of even one surgery matters, because every surgery poses a significant risk of causing permanent damage to the vocal cords and comes with potential costs to the patient, including adverse impacts to both quality of life and finances. Based on ongoing analysis of claims data, INOVIO believes there is a prevalent population of at least 25,000 patients with RRP in the United States, with additional patients diagnosed each year.

About VOCERYQ
VOCERYQ is a plasmid DNA-based immunotherapy designed to reduce the frequency of surgery for adults with RRP. VOCERYQ targets the root cause of RRP by generating an immune response using DNA plasmids that encode for HPV-6 and HPV-11 antigens. VOCERYQ is administered using the CELLECTRA 5PSP delivery device. Following a standard-of-care surgical debulking of visible papilloma prior to the initial administration of VOCERYQ, no additional surgical intervention is required as part of the 9-week dosing regimen.

The FDA previously granted VOCERYQ both Orphan Drug and Breakthrough Therapy designations, and the European Commission granted INO-3107 Orphan Drug designation. The CELLECTRA delivery device has a CE-mark in the EU, which allows INOVIO to commercialize the device in the EU and other geographies that recognize CE-marking.

Learn more at www.voceryq.com.

INDICATION
VOCERYQ is indicated to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.

This indication is approved under accelerated approval based on reduction in the frequency of surgical papilloma excisions. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory study(ies).

IMPORTANT SAFETY INFORMATION
Warnings & Precautions: Injection site reactions have occurred with VOCERYQ injection. Monitor patients for local site reactions for at least 30 minutes after treatment and manage accordingly.

Electroporation Related Adverse Reactions: Procedure-related effects including muscle contractions, transient bleeding, and vasovagal reactions may occur. Avoid use in patients with ipsilateral ICDs/pacemakers, metal implants or skin abnormalities at treatment site.

Adverse Reactions: Most common adverse reactions (incidence >5%) are injection site reactions, headache, fatigue, hypertension, nausea and dizziness.

Please go to www.voceryq.com for full Prescribing Information, including Patient Information.

(Press release, Inovio, NOV 18, 2026, View Source [SID1234674913])

Anixa Biosciences and Curia will Develop Final Formulation for Breast Cancer Vaccine in Preparation for Phase 2 Clinical Trial

On November 18, 2026 Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, reported that it will work with Curia, a leading global contract development and manufacturing organization (CDMO), to provide formulation development services for Anixa’s investigational breast cancer vaccine in preparation for its upcoming Phase 2 clinical trial. The vaccine is being developed in collaboration with Cleveland Clinic.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the collaboration, Curia will support the development of a formulation designed to optimize the vaccine’s stability, consistency, and suitability for clinical manufacturing. This work represents an important step in Anixa’s preparations for Phase 2 and is intended to establish a formulation and development process capable of supporting future clinical studies and potential commercial production.

"Selection of Curia is another important milestone as we prepare to advance our breast cancer vaccine into Phase 2 clinical development," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "Our Phase 1 trial demonstrated encouraging safety and immune-response results, and we are now focused on the activities necessary to support the next stage of clinical testing. Curia brings extensive expertise in pharmaceutical formulation and manufacturing processes, and we believe their capabilities will be valuable as we work toward developing a vaccine that could ultimately help prevent breast cancer."

"Curia looks forward to providing formulation development support for Anixa’s peptide cancer vaccine," said Ranald Baillie, VP, Drug Product Development and General Manager at Curia Glasgow. "Successful formulation and product development requires looking beyond the formulation itself to understand stability, analytical performance, scalability and the requirements of aseptic manufacturing. Curia’s integrated expertise allows us to address those considerations early and develop robust processes designed to support Anixa as it advances this vaccine towards commercialization."

Anixa’s investigational breast cancer vaccine is designed to stimulate the immune system to recognize alpha-lactalbumin, a protein expressed in many breast cancers. The vaccine recently completed a Phase 1 clinical trial involving 35 women, meeting its primary endpoints and demonstrating a favorable safety and tolerability profile, with 74% of participants exhibiting protocol-defined immune responses. Anixa is preparing to advance the vaccine into Phase 2 clinical development to further evaluate its potential clinical benefits.

(Press release, Anixa Biosciences, NOV 18, 2026, View Source [SID1234674929])

Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates

On November 18, 2026 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company leveraging its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported operational highlights and financial results for the third quarter ended September 30, 2026, and provided an update on its leadership, its portfolio of AI-driven drug candidates, and its AI platforms.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The third quarter of 2026 and the weeks that followed brought significant developments for Lantern. The Company closed a financing at the end of the quarter for gross proceeds of approximately $4.0 million. In November, the first clinical site was engaged to commence initial enrollment for a Phase 1b/2 trial in relapsed or refractory triple-negative breast cancer ("TNBC"). In September, Lantern received Taiwan regulatory and IRB approvals to open Part 2 of the Phase 2 HARMONIC trial of LP-300 in L858R never-smoker NSCLC, and in November the Company announced the peer-reviewed publication of Phase 1a LP-184 data in recurrent glioblastoma supporting a planned Phase 1b/2a combination trial with spironolactone.

Clinical Pipeline Developments

Lantern’s AI-driven clinical pipeline encompasses three clinical-stage drug candidates — LP-300, LP-184, and LP-284 — across solid tumors, blood cancers, and pediatric oncology. Each program has been guided by the RADR platform’s AI-driven insights, which are aimed at compressing the cost and timeline of cancer drug development.

LP-300 HARMONIC Trial: Taiwan Approvals Open Part 2. In September 2026, the Taiwan Food and Drug Administration (TFDA) approved the amended protocol for the Phase 2 HARMONIC trial (NCT05456256), and the lead Taiwan site received local Institutional Review Board (IRB) approval on September 29, 2026. The lead site is open to accrual and actively screening patients, and the TFDA approval allows additional Taiwan sites to proceed with their own IRB reviews; Lantern anticipates IRB approval at two additional sites during the fourth quarter of 2026. In the United States, a central IRB has approved the amended protocol, and academic clinical sites have begun identifying patients whose tumors carry the EGFR exon 21 L858R mutation.

Part 2 implements the protocol amendments to which the FDA raised no objections following the Company’s May 2026 Type C meeting request: enrollment is limited to never-smoker patients with the EGFR exon 21 L858R mutation who have progressed after tyrosine kinase inhibitor treatment, and LP-300 may be given for up to eight cycles, increased from six, in combination with carboplatin and pemetrexed. The extension is supported by HARMONIC data in which L858R patients who completed six cycles of LP-300 had a median progression-free survival of 8.9 months (n=9; three had not yet progressed), with a safety profile comparable to that of patients who received four cycles, and by prior clinical experience in which up to eight cycles at the current dose did not alter LP-300’s safety profile. These data are preliminary, exploratory and based on small patient numbers.

Taiwan offers a large, well-characterized patient population to assist with Part 2. More than half of lung cancer patients in Taiwan have never smoked, and EGFR mutations are found in 55% of advanced lung adenocarcinomas there and in roughly half across Asia, compared with approximately 14% of NSCLC in Europe and 24% in the United States; the L858R mutation is also more common in Asian patients. Taiwan’s National Health Insurance reimburses next-generation sequencing at the time of drug resistance, which the Company expects to support efficient enrollment. Having completed targeted enrollment in Japan across five clinical centers in 2025, Lantern believes data from Taiwan and Japan will be relevant to the broader East Asian population and is exploring regional licensing, partnering and co-development opportunities for LP-300.

LP-184 (zirdafulven). LP-184 has shown promising in vitro and in vivo anticancer activity in multiple solid tumor indications, including triple-negative breast, bladder, lung, glioblastoma and pancreatic cancers. With enrollment completed in the LP-184 Phase 1a trial, multiple LP-184 clinical studies are now moving forward, consisting of the FDA-cleared Phase 1b/2 trial in relapsed or refractory triple-negative breast cancer and the EMA-cleared, investigator-initiated Phase 1b/2 trial in biomarker-selected advanced bladder cancer at Rigshospitalet in Denmark.

LP-184 in Advanced Bladder Cancer: EMA-Cleared Phase 1b/2 Trial in Denmark. In July 2026, Lantern announced that the EMA cleared an investigator-initiated, open-label Phase 1b/2 trial of LP-184 in patients with advanced or metastatic urothelial carcinoma who have progressed on, or are ineligible for, standard-of-care therapy, including enfortumab vedotin plus pembrolizumab. The study is sponsored and led by Professor Kristoffer Staal Rohrberg, MD, PhD, at Rigshospitalet in Copenhagen, with Professor Helle Pappot, MD, DMSc, as coordinating investigator. It is among the first studies to prospectively select patients using a dual-biomarker strategy — overexpression of PTGR1, the enzyme that activates LP-184, combined with tumor DNA-damage-repair deficiency — to identify the tumors believed most likely to respond.

LP-184 (STAR-001) in Glioblastoma: Peer-Reviewed Phase 1a Publication. In November 2026, Lantern and its wholly-owned subsidiary Starlight Therapeutics announced the publication of Phase 1a clinical data for LP-184 in patients with recurrent GBM in the October 2026 issue of Cancer Research Communications, a peer-reviewed journal of the American Association for Cancer Research (AACR) (Free AACR Whitepaper). The work was led by investigators at Johns Hopkins University School of Medicine, the Sidney Kimmel Comprehensive Cancer Center and the Hugo W. Moser Research Institute at Kennedy Krieger, together with Lantern scientists. LP-184 was generally well tolerated in 16 heavily pretreated patients with recurrent GBM enrolled in the 63-patient Phase 1a study, with a safety profile consistent with the broader solid tumor population. The study confirmed a recommended dose for expansion of 0.39 mg/kg, given intravenously on days 1 and 8 of each 21-day cycle. Consistent with the projected limited brain exposure of LP-184 as a single agent, no objective radiographic responses were observed; one patient with MGMT-methylated GBM at first recurrence has remained clinically and radiographically stable for more than 22 months after enrollment.

Because only about 20% of systemic LP-184 is expected to reach brain tumors, Lantern is pairing LP-184 with spironolactone, an FDA-approved, brain-penetrant drug that triggers degradation of ERCC3, a key protein in the DNA repair pathway GBM cells use to survive LP-184. In orthotopic GBM patient-derived xenograft models, three daily doses of spironolactone reduced tumor ERCC3 levels by approximately 80% and approximately doubled LP-184-induced tumor cell death, and pharmacokinetic modeling based on Phase 1a patient data projects that the combination will reach intratumoral LP-184 concentrations approximately 2- to 3-fold above those needed to kill GBM cells. These findings provide the dosing basis for the planned Phase 1b/2a trial (NCT07431216), sponsored by Starlight under an FDA-cleared IND, to evaluate LP-184 (STAR-001) plus spironolactone in patients with GBM at first recurrence after standard temozolomide-based therapy, subject to obtaining additional funding.

LP-284 Development; and STAR-001 (LP-184) in Pediatric CNS Cancers. LP-284, the enantiomer of LP-184, is in a Phase 1a clinical trial in hematologic malignancies and adult soft tissue sarcomas. In September 2026, Lantern announced that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 18/500,032, "Method for Treating Blood Cancers," with claims directed to the use of LP-284 to treat mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). Lantern’s subsidiary Starlight Therapeutics holds a cleared IND for a planned Phase 1 pediatric CNS cancer trial of STAR-001 (LP-184).

Open Medicine AI

In July 2026, Lantern formed Open Medicine AI Inc. (OMAI) as a wholly-owned subsidiary to commercialize and expand the multi-agentic AI co-scientist platform originally launched as withZeta.ai. In connection with its formation, Lantern entered into asset contribution and license agreements granting OMAI access to Lantern’s withZeta.ai-related models, data, algorithms, and other assets. OMAI inherits the full multi-agentic system, including coordinated specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy, biomarkers and translational science, clinical oncology, and general research; three research modes (Explorer, Investigator, and Reporter); proprietary rare-cancer knowledge bases and ontologies; and expanding computational layers, including ZetaOmics for multi-omic analysis. While rare cancers and oncology remain core, OMAI’s planned roadmap includes systematic expansion into additional high-need disease areas, particularly in collaboration with leading academic and commercial partners. Lantern believes that establishing OMAI as a separate business will facilitate access to dedicated funding sources and may allow realization of value separate from the Company’s drug development operations.

Leadership Transition

On November 15, 2026, Panna Sharma resigned as President and Chief Executive Officer of Lantern Pharma, effective November 15, 2026. Mr. Sharma also resigned from the Company’s Board of Directors, effective November 15, 2026.

Effective November 16, 2026, the Board appointed David Margrave, the Company’s Chief Financial Officer, as Interim Chief Executive Officer until the Company appoints a permanent Chief Executive Officer. The Board intends to promptly commence a search for a successor.

Proposed Settlement

In November 2026, the Company reached an agreement in principle regarding a settlement agreement with a former part-time consultant asserting claims of disability discrimination, sexual harassment and related claims. Under the terms of the proposed settlement, the Company would pay the claimant a total of $2.0 million, consisting of $1.0 million within 30 days of the effective date of the settlement agreement and $1.0 million upon the earlier of (i) the date on which the Company has raised, in the aggregate after the effective date, at least $10.0 million in gross cash proceeds through investment in the Company, the sale of Company assets, or the out-licensing of Company patents, and (ii) the two-year anniversary of the first payment.

Although the proposed settlement is not yet finalized and is not yet effective, the Company believes its terms represent the best estimate of loss with respect to this matter. Accordingly, the Company accrued $2.0 million in accounts payable and accrued expenses as of September 30, 2026, and the corresponding expense is included in general and administrative expenses for the three and nine months ended September 30, 2026. This estimate could change in the near term, and any change may be material.

Financial Results for the Third Quarter Ended September 30, 2026

Balance Sheet: Cash, cash equivalents, and marketable securities were approximately $7.6 million as of September 30, 2026, compared to approximately $10.1 million as of December 31, 2025. Funding received during the third quarter consisted of approximately $4.0 million in gross proceeds, before offering expenses of approximately $0.4 million, from the registered direct offering that closed on September 30, 2026. The Company intends to pursue periodic capital raises, including potential sales under its ATM facility, as well as collaborations, grant funding and other opportunities to extend its operating runway. The Company’s cash, cash equivalents, and marketable securities as of the date of its Q3 2026 Quarterly Report on Form 10-Q are not sufficient to fund operations at the current level for the next 12 months, and there is substantial doubt about the Company’s ability to continue as a going concern in the absence of obtaining substantial additional funding.

Research and Development Expenses: R&D expenses were approximately $1.6 million for the three months ended September 30, 2026, compared to approximately $2.4 million for the three months ended September 30, 2025, a decrease of approximately $0.87 million or 36%. The decrease was primarily attributable to reductions of approximately $0.69 million in research studies and materials costs relating to the conduct and support of our clinical trials.

General and Administrative Expenses: G&A expenses were approximately $3.8 million for the three months ended September 30, 2026, compared to approximately $1.9 million for the three months ended September 30, 2025, an increase of approximately $1.9 million or 99%. The increase was primarily attributable to a $2.0 million accrual for the proposed settlement, together with increases of approximately $0.13 million in salaries and benefit expenses, partially offset by decreases of approximately $0.23 million in business development and investor relations expenses. Excluding the accrual for the proposed settlement, G&A expenses were approximately $1.8 million, a decrease of approximately 5% year over year.

Operating Loss: Loss from operations was approximately $5.4 million for the three months ended September 30, 2026, compared to approximately $4.3 million for the three months ended September 30, 2025, an increase of approximately 24%. Excluding the $2.0 million accrual for the proposed settlement, loss from operations was approximately $3.4 million, a decrease of approximately 22% year over year.

Warrant Accounting: The investor and placement agent warrants issued in the Company’s May 2026 offering are accounted for as liabilities due to a settlement feature that may be triggered in the event of a fundamental transaction, and are remeasured at fair value each quarter. During the three months ended September 30, 2026, the estimated fair value of these warrants decreased by approximately $6.0 million, due primarily to a decrease in the Company’s stock price, resulting in a non-cash gain. The warrant liability was approximately $1.5 million as of September 30, 2026. The warrants issued in the September 2026 offering are classified within equity and are not subject to quarterly fair value remeasurement.

Net Income (Loss): After including the non-cash warrant gain, net income was approximately $0.7 million (or $0.05 per basic share) for the three months ended September 30, 2026, compared to a net loss of approximately $4.2 million (or $0.39 per share) for the three months ended September 30, 2025.

Capitalization: As of September 30, 2026, the Company had 14,935,576 shares of common stock outstanding. On September 30, 2026, the Company closed a registered direct offering and concurrent private placement with an institutional investor comprising 1,469,725 shares of common stock at $1.09 per share, pre-funded warrants to purchase up to 2,200,000 shares of common stock, warrants to purchase up to 3,669,725 shares of common stock at an exercise price of $1.09 per share, and placement agent warrants to purchase up to 183,485 shares at an exercise price of $1.3625 per share. On September 22, 2026, the pre-funded warrants issued in the May 2026 offering were exercised on a cashless basis for 681,705 shares, and on October 26, 2026, a portion of the September 2026 pre-funded warrants was exercised for 926,000 shares. As of November 9, 2026, the Company had 15,886,576 shares of common stock outstanding.

Additional detail is available in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission.

Loss from operations excluding the proposed settlement accrual is a non-GAAP financial measure. Management believes this measure is useful to investors because it excludes a non-recurring charge and facilitates comparison of the Company’s ongoing operating costs between periods. It should be considered in addition to, and not as a substitute for, loss from operations determined in accordance with GAAP, and may not be comparable to similarly titled measures used by other companies.

(Press release, Lantern Pharma, NOV 18, 2026, View Source [SID1234674914])